HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Epidemiological and therapeutic studies on gonorrheal infections--clinical efficacy of T-2588. (Sapporo Clinical Research Group for STD)].

Abstract
T-2588, a new oral cephalosporin antibiotic, for gonorrheal infections, was administered to 146 patients with gonorrheal infection cases (140 urethritis cases in males, 6 cervicitis cases in females). Twenty three strains (20.9%) out of 110 clinically isolated gonococci were PPNG. The MICs of T-2588 for the clinically isolated gonococci strains showed a distribution peak at 0.025 microgram/ml and ranged between 0.0125 microgram/ml to 0.1 microgram/ml when an inoculum size of 10(6)/CFU/ml was used. The distribution of MICs of PPNG also showed a peak at 0.025 microgram/ml and the maximum MIC was 0.2 microgram/ml, which is one dilution tube higher than the maximum MIC of non-PPNG. The rate of complication by Chlamydia trachomatis was 20.9% in male and 33.3% in female. At the dose of 400 mg given 2 times a day, the efficacy rate for the males on the 3rd and 7th day was 90.5% (efficacy rate against PPNG, 73.3%) and 95.3% (80.0%), respectively. At the dose of 300 mg given 3 times a day, it was 93.3% and 100%, respectively, and at the dose of 600 mg given 3 times a day, it was 100% and 100%, respectively. Therefore, the administration of T-2588 3 times a day resulted in a higher efficacy rate than that given 2 times a day. This effect was extremely marked in the case of patients with PPNG. The best clinical results were obtained at a daily dose of 600 mg t.i.d. Although the female patients were few, in number and no conclusion can be drawn, the best results were obtained with a daily dose of 600 mg t.i.d. (100%). There were three mild side effects (1.7%), which could not be attributed to the administration of T-2588 in the present study. In conclusion, T-2588 can be to be expected sufficiently clinically effective against gonorrheal infections, including PPNG, at a daily dose of 600 mg t.i.d. for 3 days.
AuthorsY Kumamoto, S Sakai, T Tsunekawa, S Okayama, T Gohro, T Inoke, S Tabata, H Tanda, S Kato, K Igawa
JournalHinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 32 Issue 10 Pg. 1551-72 (Oct 1986) ISSN: 0018-1994 [Print] Japan
PMID3105273 (Publication Type: Journal Article)
Chemical References
  • Cephalosporins
  • cefteram pivoxil
  • Cefmenoxime
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Cefmenoxime (analogs & derivatives)
  • Cephalosporins (administration & dosage, therapeutic use)
  • Drug Evaluation
  • Drug Resistance, Microbial
  • Female
  • Gonorrhea (drug therapy, microbiology, transmission)
  • Humans
  • Male
  • Middle Aged
  • Neisseria gonorrhoeae (drug effects, isolation & purification)
  • Sex Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: